Clinical management of negative symptoms of schizophrenia: An update

Pharmacology and Therapeutics

Volumn 153, Issue , 2015, Pages 135-147

  Tsapakis, Evangelia M ^a,b   Dimopoulou, Trisevgeni ^a   Tarazi, Frank I ^b  

^a Aghios Charalambos Mental Health Centre   (Greece)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Negative symptoms; Neurochemistry; Non pharmacological treatments; Novel pharmacological treatments

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOOXYGENASE 2; ESSENTIAL FATTY ACID; GLUTAMIC ACID; MINOCYCLINE; NEUROLEPTIC AGENT; PREGNENOLONE; PSYCHOSTIMULANT AGENT; SEROTONIN 3 ANTAGONIST; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIINFLAMMATORY AGENT; PSYCHOTROPIC AGENT;

ART THERAPY; ARTICLE; BRIEF NEGATIVE SYMPTOM SCALE; BRIEF PSYCHIATRIC RATING SCALE; CHOLINERGIC SYSTEM; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DOPAMINERGIC SYSTEM; ELECTROCONVULSIVE THERAPY; FAMILY THERAPY; GENERAL MENTAL DISEASE ASSESSMENT; GENETIC VARIABILITY; HUMAN; NEGATIVE SYMPTOM ASSESSMENT; NEGATIVE SYNDROME; NONHUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; ANIMAL; GENETICS; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTHERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; ELECTROCONVULSIVE THERAPY; HUMANS; NEUROTRANSMITTER AGENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84938419777     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.06.008     Document Type: Review

References (193)

1. A. Abi-Dargham Do we still believe in the dopamine hypothesis? New data bring new evidence Int J Neuropsychopharmacol 7 2004 S1 S5
2. 1 receptors and working memory in schizophrenia J Neurosci 22 2002 3708 3719
3. N.C. Allen, S. Bagade, M.B. McQueen, J.P. Ioannidis, F.K. Kavvoura, M.J. Khoury, and et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database Nat Genet 40 2008 827 834
4. L.D. Alphs, R. Morlock, C. Coon, A. van Willigenburg, and J. Panagides The 4-item negative symptom assessment (NSA-4) instrument. A simple tool for evaluating negative symptoms in schizophrenia following brief training Psychiatry 7 2010 26 32
5. L.D. Alphs, A. Summerfelt, H. Lann, and R.J. Muller The negative symptom assessment: A new instrument to assess negative symptoms of schizophrenia Psychopharmacol Bull 25 1989 159 163
6. A.C. Amaresha, and G. Venkatasubramanian Expressed emotion in schizophrenia: An overview Indian J Psychol Med 34 2012 12 20
7. M. Amr, S.E. Lakhan, S. Sanhan, D. Al-Rhaddad, M. Hassan, M. Thiabh, and et al. Efficacy and tolerability of quetiapine versus haloperidol in first episode schizophrenia: A randomized clinical trial Int Arch Med 6 1 2013 47
8. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X.S. Hu, A. Cappiello, and et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for the hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists Arch Gen Psychiatry 57 2000 270 276
9. N.C. Andreasen The scale for the assesment of negative symptoms (SANS): Conceptual and theoretical foundations Br J Psychiatry 7 1989 49 58
10. M. Arbabi, M. Bagheri, F. Rezaei, S.A. Ahmadi-Abhari, M. Tabrizi, F. Khalighi-Sigaroudi, and et al. A placebo-controlled study of modafinil added to risperidone in chronic schizophrenia Psychopharmacology (Berl) 220 2012 591 598
11. H. Ashdown, Y. Dumont, M. Nq, S. Poole, P. Boksa, and G.N. Luheshi The role of cytokines in mediating effects of prenatal infection on the fetus: Implications for schizophrenia Mol Psychiatry 11 2006 47 55
12. B.N. Axelrod, R.S. Goldman, and L.D. Alphs Validation of the 16-item negative symptom scale J Psychiatr Res 27 1993 253 258
13. R.J. Baldessarini Schizophrenia N Engl J Med 297 1977 988 995
14. R.J. Baldessarini, and F.I. Tarazi L.L. Brunton, J.S. Lazo, K.L. Parker, Pharmacotherapy of psychosis and mania Goodman and Gilman's the pharmacological basis of therapeutics Vol. 11 2005 McGraw-Hill New York
15. D.M. Barch The CAINS: Theoretical and practical advances in the assessment of negative symptoms in schizophrenia Am J Psychiatry 170 2013 133 135
16. A. Barker, R. Jalinous, and I. Freeston Non-invasive magnetic stimulation of the human motor cortex Lancet 325 1985 1106 1107
17. M.S. Barr, F. Farzan, L.C. Tran, P.B. Fitzgerald, and Z.J. Daskalakis A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia Brain Stimul 5 2012 337 346
18. A. Bechdolf, B. Knost, C. Kuntermann, S. Schiller, J. Klosterkötter, M. Hambrecht, and et al. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia Acta Psychiatr Scand 110 2004 21 28
19. A.T. Beck Cognitive therapy and the emotional disorders 1976 International Universities Press New York
20. A.T. Beck, and N.A. Rector Cognitive approaches to schizophrenia: Theory and therapy Annu Rev Clin Psychol 1 2005 577 606
21. A.C. Bennett, and T.M. Vila The role of ondansetron in the treatment of schizophrenia Ann Pharmacother 44 2010 1301 1306
22. M. Berk, C. Ichim, and S. Brook Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study Int Clin Psychopharmacol 16 2001 87 92
23. K.C. Berridge, and M.L. Kringelbach Pleasure systems in the brain Neuron 86 3 2015 646 664
24. 158 Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia Schizophr Res 95 2007 253 255
25. J.J. Blanchard, and A.S. Cohen The structure of negative symptoms within schizophrenia: Implications for assessment Schizophr Bull 32 2006 238 245
26. J. Bobes, C. Arango, M. Garcia-Garcia, J. Rejas CLAMORS Study Collaborative Group Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study J Clin Psychiatry 71 2010 280 286
27. A. Breier, R.W. Buchanan, B. Kirkpatrick, O.R. Davis, D. Irish, A. Summerfelt, and et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia Am J Psychiatry 151 1994 20 26
28. G.G. Brown, and W.K. Thompson Functional brain imaging in schizophrenia: Selected results and methods Curr Top Behav Neurosci 4 2010 181 214
29. R.W. Buchanan Persistent negative symptoms in schizophrenia: An overview Schizophr Bull 33 2007 1013 1022
30. R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler, J.M. Gold, R.P. McMahon, and et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am J Psychiatry 164 2007 1593 1602
31. P.F. Buckley, and S.M. Stahl Pharmacological treatment of negative symptoms of schizophrenia: Therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 115 2007 93 100
32. G. Caforio, A. Di Giorgio, A. Rampino, M. Rizzo, R. Romano, P. Taurisano, and et al. Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia J Clin Psychopharmacol 33 2013 810 812
33. A. Carlsson, and M. Lindqvist Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain Acta Pharmacol 20 1963 140 144
34. A. Caspi, T.E. Moffitt, M. Cannon, J. McClay, R. Murray, H. Harrington, and et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-menthyltransferase gene: Longitudinal evidence of a gene × environment interaction Biol Psychiatry 57 2005 1117 1127
35. W. Chanpattana, and H.A. Sackeim Electroconvulsive therapy in treatment-resistant schizophrenia: Prediction of response and the nature of symptomatic improvement J ECT 26 2010 289 298
36. I.B. Chaudhry, J. Hallak, N. Husain, F. Minhas, J. Stirling, P. Richardson, and et al. Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment J Psychopharmacol 26 2012 1185 1193
37. S.J. Cho, K. Yook, B. Kim, T.K. Choi, K.S. Lee, Y.W. Kim, and et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial Prog Neuropsychopharmacol Biol Psychiatry 35 2011 208 211
38. K.H. Choi, T. Wykes, and M.M. Kurtz Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy Br J Psychiatry 203 2013 172 178
39. P. Chue Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1) Curr Pharm Des 19 2013 1311 1320
40. L. Citrome, J. Levine, and B. Allingham Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994-1998 Psychiatr Serv 51 2000 634 638
41. L.A. Clarke, C.W. Cassidy, G. Catalano, M.C. Catalano, and K.M. Carroll Psychosis induced by smoking cessation clinic administered anticholinergic overload Ann Clin Psychiatry 16 2004 171 175
42. S.M. Clinton, and J.H. Meador-Wooddruff Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder Neuropsychopharmacology 29 2004 1353 1362
43. A.S. Cohen, G.M. Najolia, L.A. Brown, and K.S. Minor The state-trait disjunction of anhedonia in schizophrenia: Potential affective, cognitive and social-based mechanisms Clin Psychol Rev 31 2011 440 448
44. C.I. Cohen, N. Natarajan, M. Araujo, and D. Solanki Prevalence of negative symptoms and associated factors in older adults with schizophrenia spectrum disorder Am J Geriatr Psychiatry 21 2013 100 107
45. M.J. Crawford, H. Killaspy, T.R. Barnes, B. Barrett, S. Byford, K. Clayton, and et al. Group art therapy as an adjunctive treatment for people with schizophrenia: A randomised controlled trial (MATISSE) Health Technol Assess 16 8 2012 iii iv (1-76)
46. I. Creese, I.R. Burt, and S.H. Snyder Dopamine reception binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
47. J. Darba, A. Minoves, E. Rojo, F. Jimenez, and J. Rejas Efficacy of second-generation antipsychotics in the treatment of negative symptoms of schizophrenia: A meta-analysis of randomized clinical trials Rev Psiquiatr Salud Ment 4 2011 126 143 (English Edition)
48. D. de Lucena, B.S. Fernandes, M. Berk, S. Dodd, D.W. Medeiros, M. Pedrini, and et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine J Clin Psychiatry 70 2009 1416 1423
49. J.E. Desmarais, L. Beauclair, and H.C. Margolese Anticholinergics in the era of atypical antipsychotics: Short-term or long-term treatment? J Psychopharmacol 26 2012 1167 1174
50. J.J. Dlabac-de Lange, R. Knegtering, and A. Aleman Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: Review and meta-analysis J Clin Psychiatry 71 2010 411 418
51. D.G. Dyck, R.A. Short, M.S. Hendryx, D. Norell, M. Myers, T. Patterson, and et al. Management of negative symptoms among patients with schizophrenia attending multiple-family groups Psychiatr Serv 51 4 2000 513 519
52. C.J. Edgar, T. Blaettler, D. Bugarski-Kirola, S. Le Scouiller, G.M. Garibaldi, and S.R. Marder Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms Psychiatry Res 218 2014 219 224
53. L.M. Ellman, A.L. Cook, C.A. Schaefer, M.A. Bresnahan, E.S. Susser, and A.S. Brown Maternal inflammation during pregnancy and symptom profiles of offspring diagnosed with schizophrenia Brain Behav Immun 40 Suppl. 2014 e33
54. S.M. Erhart, S.R. Marder, and W.T. Carpenter Treatment of schizophrenia negative symptoms: Future prospects Schizophr Bull 32 2006 234 237
55. A. Essali, N. Al-Haj Haasan, C. Li, and J. Rathbone Clozapine versus typical neuroleptic medication for schizophrenia Cochrane Database Syst Rev 21 2009 CD000059
56. A.H. Fanous, E.J. van den Oord, B.P. Riley, S.H. Aggen, M.C. Neale, and F.A. O'Neill Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia Am J Psychiatry 162 2005 1824 1832
57. M. Farokhnia, A. Azarkolah, F. Adinehfar, M.R. Khodaie-Ardakani, S.M. Hosseini, H. Yekehtaz, and et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled study Clin Neuropharmacol 36 2013 185 192
58. G. Fervaha, A. Graff-Guerrero, K.K. Zakzanis, G. Foussias, O. Agid, and G. Remington Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making J Psychiatr Res 47 11 2013 1590 1596
59. D.J. Foster, C.K. Jones, and P.J. Conn Emerging approaches for treatment of schizophrenia: Modulation of cholinergic signaling Discov Med 14 2012 413 420
60. J.I. Friedman Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists Psychopharmacology (Berl) 174 2004 45 53
61. M.P. Garcia-Portilla, L. Garcia-Alvarez, P.A. Saiz, S. Al-Halabi, M.T. Bobes-Bascaran, M.T. Bascaran, and et al. Psychometric evaluation of the negative syndrome of schizophrenia Eur Arch Psychiatry Clin Neurosci 2015 10.1007/s00406-015-0595-z
62. D.E. Gard, A.M. Kring, M.G. Gard, W.P. Horan, and M.F. Green Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure Schizophr Res 93 2007 253 260
63. M. Girón, A. Fernández-Yañez, S. Mañá-Alvarenga, A. Molina-Habas, A. Nolasco, and M. Gómez-Beneyto Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: A 2-year randomized controlled study Psychol Med 40 2010 73 84
64. D.C. Goff, R. Keefe, L. Citrome, K. Davy, J.H. Krystal, C. Large, and et al. Lamotrigine as add-on therapy in schizophrenia: Results of 2 placebo-controlled trials J Clin Psychopharmacol 27 2007 582 589
65. J.M. Gold, J.A. Waltz, K.J. Prentice, S.E. Morris, and E.A. Heerey Reward processing in schizophrenia: A deficit in the representation of value Schizophr Bull 34 5 2008 835 847
66. D.J. Haleem Extending therapeutic use of psychostimulants: Focus on serotonin-1A receptor Prog Neuropsychopharmacol Biol Psychiatry 46 2013 170 180
67. P.J. Harrison, and M.J. Owen Genes for schizophrenia? Recent findings and their pathophysiological implications Lancet 361 2003 417 419
68. K. Hinkelmann, A. Yassouridis, M. Kellner, H. Jahn, K. Wiedemann, and T.J. Raedler No effects of antidepressants on negative symptoms in schizophrenia J Clin Psychopharmacol 33 5 2013 686 690
69. U. Hiroshi Stimulant-induced psychosis and schizophrenia: The role of sensitization Curr Psychiatry Rep 4 2002 177 184
70. S. Holttum, and V. Huet The MATISSE trial - A critique does art therapy really have nothing to offer people with a diagnosis of schizophrenia? SAGE Open 4 2 2014 10.1177/2158244014532930
71. O.D. Howes, and S. Kapur The dopamine hypothesis of schizophrenia: Version III - The final common pathway Schizophr Bull 35 2009 549 562
72. P.H. Hutson, F.I. Tarazi, M. Madhoo, C. Slawecki, and A.A. Patkar Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders Pharmacol Ther 143 2014 253 264
73. J. Ichikawa, Y.C. Chung, Z. Li, J. Dai, and H.Y. Meltzer Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens Brain Res 958 2002 176 184
74. K. Ishizuka, M. Paek, A. Kamiya, and A. Sawa A review of Disrupted-In-Schizophrenia-1 (DISC1): Neurodevelopment, cognition, and mental conditions Biol Psychiatry 59 2006 1189 1197
75. D.C. Javitt Glutamate and schizophrenia: Phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions Int Rev Neurobiol 78 2007 69 108
76. D.C. Javitt Twenty-five years of glutamate in schizophrenia: Are we there yet? Schizophr Bull 38 2012 911 913
77. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1991 1301 1318
78. P.B. Jones, T.R. Barnes, L. Davies, G. Dunn, H. Lloyd, K.P. Hayhurst, and et al. Randomized controlled trial of effect on quality of life of second-vs. first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) Arch Gen Psychiatry 63 2006 1079 1087
79. C. Jones, D. Hacker, I. Cormac, A. Meaden, and C.B. Irving Cognitive behavior therapy versus other psychosocial treatments for schizophrenia Cochrane Database Syst Rev 4 2012 CD008712
80. C.B. Joy, R. Mumby-Croft, and L.A. Joy Polyunsaturated fatty acid supplementation for schizophrenia Cochrane Database Syst Rev 3 2006 CD001257
81. E. Jung, M. Wiesjahn, and T.M. Lincoln Negative, not positive symptoms predict the early therapeutic alliance in cognitive behavioral therapy for psychosis Psychother Res 24 2014 171 178
82. E.R. Kandel, J.H. Schwartz, and T.M. Jessell Principles of neural sciences 4th ed 2000 McGraw-Hill New York
83. J.M. Kane, R. Yang, and J.M. Youakim Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled study Schizophr Res 135 2012 116 122
84. K.R. Kaufman Antiepileptic drugs in the treatment of psychiatric disorders Epilepsy Behav 21 2011 1 11
85. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
86. P. Khanna, K. Kommosa, H. Ma, C. Rummel-Kluge, H.G. El-Sayeh, S. Leucht, and et al. Aripiprazole versus atypical antipsychotics Cochrane Database Syst Rev 1 2014 CD006569
87. M.R. Khodaie-Ardakani, O. Mirshafiee, M. Farokhnia, M. Tajdini, S.M. Hosseini, A. Modabbernia, and et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study Psychiatry Res 215 2014 540 546
88. K. Kingwell Schizophrenia drug gets negative results for negative symptoms Nat Rev Drug Discov 13 2014 244 245
89. B. Kirkpatrick, and B. Fischer Subdomains within the negative symptoms of schizophrenia: Commentary Schizophr Bull 32 2006 246 249
90. B. Kirkpatrick, G.P. Strauss, L. Ngugen, B.A. Fischer, D.G. Daniel, A. Cienfuegos, and et al. The brief negative symptom scale: Psychometric properties Schizophr Bull 37 2011 300 305
91. S. Klingberg, W. Wölwer, C. Engel, A. Wittorf, J. Herrlich, C. Meisner, and et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: Results of the randomized clinical TONES study Schizophr Bull 37 2011 S98 S110
92. A.M. Kring, R.E. Gur, J.J. Blanchard, W.P. Horan, and S.P. Reise The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation Am J Psychiatry 170 2013 165 172
93. M.M. Kurtz Neurocognitive impairment across the lifespan in schizophrenia: An update Schizophr Res 74 2005 15 26
94. W. Laan, D.E. Grobbee, J.P. Selten, C.J. Heijnen, R.S. Kahn, and H. Burger Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial J Clin Psychiatry 71 2010 520 527
95. H.Y. Lane, Y.C. Chang, Y.C. Liu, C.C. Chiu, and G.E. Tsai Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study Arch Gen Psychiatry 62 2005 1196 1204
96. R.A. Lasser, B. Dirks, H. Nasrallah, C. Kirsch, J. Gao, M.L. Pucci, and et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: Open-label and randomized-withdrawal phases Neuropsychopharmacology 38 2013 2140 2149
97. S. Leucht, J.M. Kane, W. Kissling, J. Hamann, E. Etschel, and R. Engel Clinical implications of Brief Psychiatric Rating Scale scores Br J Psychiatry 187 2005 366 371
98. B. Leurent, H. Killaspy, D.P. Osborn, M.J. Crawford, A. Hoadley, D. Waller, and et al. Moderating factors for the effectiveness of group art therapy for schizophrenia: Secondary analysis of data from the MATISSE randomized controlled trial Soc Psychiatry Psychiatr Epidemiol 49 2014 1703 1710
99. S.Z. Levine, and S. Leucht Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms Eur Neuropsychopharmacol 23 2013 1051 1056
100. Y. Levkovitz, S. Mendlovich, S. Riwkes, Y. Braw, H. Levkovitch-Verbin, G. Gal, and et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia J Clin Psychiatry 71 2010 138 149
101. W.J. Li, C.G. Kou, Y. Yu, S. Sun, X. Zhang, T.R. Kosten, and et al. Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population Am J Med Genet 159B 2012 370 375
102. J.A. Lieberman, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, and et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 2005 1209 1223
103. J.P. Lindenmayer, H. Nasrallah, M. Pucci, S. James, and L. Citrome A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities Schizophr Res 147 2013 241 252
104. F. Liu, X. Guo, R. Wu, J. Ou, Y. Zheng, B. Zhang, and et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double-blind, randomized, controlled trial Schizophr Res 153 2014 169 176
105. 1 receptor: Focus on negative symptoms Prog Neuropsychopharmacol Biol Psychiatry 16 1992 797 832
106. S.P. Mahadik, D. Evans, and K. Lal Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 25 2001 463 493
107. S.P. Mahadik, A. Pillai, S. Joshi, and A. Foster Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia Int Rev Psychiatry 18 2006 119 131
108. S.P. Marder, and B. Kirkpatrick Defining and measuring negative symptoms of schizophrenia in clinical trials Eur Neuropsychopharmacol 24 2014 737 743
109. C.E. Marx, D.W. Bradford, R.M. Hamer, J.C. Naylor, T.B. Allen, J.A. Lieberman, and et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: Emerging preclinical and clinical evidence Neuroscience 15 2011 78 90
110. C.E. Marx, R.S.E. Keefe, R.W. Buchanan, R.M. Hamer, J.D. Kilts, D.W. Bradford, and et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia Neuropsychopharmacology 34 2009 1885 1903
111. M. Mazza, M. Pomponi, L. Janiri, P. Bria, and S. Mazza Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview Prog Neuropsychopharmacol Biol Psychiatry 31 2007 12 26
112. H.Y. Meltzer Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia Psychopharmacology (Berl) 99 1989 S18 S27
113. H. Meltzer, and A. Kostacoglu Treatment-resistant schizophrenia J. Lieberman, R. Murray, Comprehensive care of schizophrenia: A textbook of clinical management 2001 Martin Dunitz London 181 203
114. U. Meyer, M. Nyffeler, S. Schwendener, I. Knuesel, B.K. Yee, and J. Feldon Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge Neuropsychopharmacology 33 2008 441 456
115. T. Miyoka, R. Yasukawa, K. Yasuda, M. Hayashida, T. Inagaki, and J. Horiguchi Minocycline as adjunctive therapy for schizophrenia: An open-label study Clin Neuropharmacol 31 2008 287 292
116. H.J. Moller Management of the negative symptoms of schizophrenia CNS Drugs 17 2000 793 823
117. A.S. Monte, G.C. de Souza, R.S. McIntyre, J.K. Soczynska, J.V. dos Santos, R.C. Cordeiro, and et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitregic pathways J Psychopharmacol 27 2013 1032 1043
118. F. Mottaghy, C. Keller, M. Gangitano, J. Ly, M. Thall, J.A. Parker, and et al. Correlation of cerebral blood flow and treatment effects of repetitive transcranial magnetic stimulation in depressed patients Psychiatry Res 115 2002 1 14
119. N. Müller, D. Krause, S. Dehning, R. Musil, R. Schennach-Wolff, M. Obermeier, and et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment Schizophr Res 121 2010 118 124
120. T. Nasr, and R. Kausar Psychoeducation and the family burden in schizophrenia: A randomized controlled trial Ann Gen Psychiatry 8 2009 17
121. H.A. Nasrallah, and D.R. Weinberger Handbook of schizophrenia volume I: The Neurology of schizophrenia 1986 Elsevier Amsterdam
122. J.C. Neill, M.K. Harte, P.M. Haddad, E.S. Lydall, and D.M. Dwyer Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational links to humans Eur Neuropsychopharmacol 24 2014 822 835
123. Y. Noda, H. Kamei, T. Mamiya, H. Furukawa, and T. Nabeshima Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: Imbalance of prefrontal serotonergic and dopaminergic functions Neuropsychopharmacology 23 2000 375 387
124. M. Noroozian, S. Ghasemi, S.M. Hosseini, A. Modabbernia, M.R. Khodaie-Ardakani, O. Mirshafiee, and et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia Psychopharmacology (Berl) 228 2013 595 602
125. S. Ogino, S. Miyamoto, N. Miyake, and N. Yamaguchi Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function Psychiatry Clin Neurosci 68 2014 37 49
126. 1 receptors in schizophrenia revealed by PET Nature 385 6617 1997 634 636
127. J.E. Overall, and D.R. Gorham The Brief Psychiatric Rating Scale Psychol Rep 10 1962 799 812
128. I.H. Park, J.W. Chun, H.J. Park, M.S. Koo, S. Park, S.H. Kim, and et al. Altered cingulo-striatal function underlies reward drive deficits in schizophrenia Schizophr Res 161 2-3 2015 229 236
129. R. Patel, N. Jayatilleke, R. Jackson, R. Stewart, and P. McGuire Investigation of negative symptoms in schizophrenia with a machine learning text-mining approach Lancet 383 2014 S16
130. Pelayo-Terán J.M., R. Pérez-Iglesias, J. Vázquez-Bourgon, I. Mata, E. Carrasco-Marín, J.L. Vázquez-Barquero, and et al. Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis Psychiatry Res 185 2011 286 289
131. J.H. Peloian, and J.M. Pierre Modafinil: A candidate for pharmacotherapy of negative symptoms of schizophrenia Prog Neurother Neuropsychopharmacol 3 2008 259 274
132. I. Perez-Neri, J. Ramirez-Bermudez, S. Montes, and C. Rios Possible mechanisms of neurodegeneration in schizophrenia Neurochem Res 31 2006 1279 1294
133. D. Perivoliotis, and C. Cather Cognitive behavioral therapy of negative symptoms J Clin Psychol 65 2009 815 830
134. M.R. Philips, V. Pearson, F. Li, M. Xu, and L. Yang Stigma and expressed emotion: A study of people with schizophrenia and their family members in China Br J Psychiatry 181 2002 488 493
135. V. Pilla Reddy, M. Kozielska, A.A. Suleiman, M. Johnson, A. Vermeulen, J. Liu, and et al. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score Schizophr Res 146 2013 153 161
136. L.S. Pilowsky, R.A. Bressan, J.M. Stone, K. Erlandsson, R.S. Mulligan, J.H. Krystal, and et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients Mol Psychiatry 11 2005 118 119
137. T.S. Premkumar, and J. Pick Lamotrigine for schizophrenia Cochrane Database Syst Rev 4 2006 CD005962
138. L. Rabany, L. Deutsch, and Y. Levkovitz Double-blind, randomized sham controlled study of deep-TMS add-on treatment for negative symptoms and cognitive deficits in schizophrenia J Psychopharmacol 28 2014 686 690
139. L. Rabany, M. Weiser, N. Weberloff, and Y. Levkovitz Assessment of negative symptoms and depression in schizophrenia: Revision of the SANS and how it related to the PANSS and CDSS Schizophr Res 126 2011 226 230
140. T.J. Raedler, F.P. Bymaster, R. Tandon, D. Copolov, and B. Dean Towards a muscarinic hypothesis of schizophrenia Mol Psychiatry 12 2007 232 246
141. T.J. Raedler, M.B. Knable, D.W. Jones, R.A. Urbina, J.G. Gorey, K.S. Lee, and et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia Am J Psychiatry 160 2003 118 127
142. F. Rezaei, M. Mohammad-Karimi, S. Seddighi, A. Modabbernia, M. Ashrafi, B. Salehi, and et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized, double-blind, placebo-controlled study J Clin Psychopharmacol 33 2013 336 342
143. P. Richardson, K. Jones, C. Evans, P. Stevens, and A. Rowe Exploratory RCT of art therapy as an adjunctive treatment in schizophrenia J Ment Health 16 2007 483 491
144. M.S. Ritsner, H. Bawakny, and A. Kreinin Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two center trial Psychiatry Clin Neurosci 68 2014 432 440
145. K. Rømer Thomsen, P.C. Whybrow, and M.L. Kringelbach Reconceptualizing anhedonia: Novel perspectives on balancing the pleasure networks in the human brain Front Behav Neurosci 9 2015 49 10.3389/fnbeh.2015.00049
146. R.M. Roth, L.A. Flashman, A.J. Saykin, T.W. McAllister, and R. Vidaver Apathy in schizophrenia: Reduced frontal lobe volume and neuropsychological deficits Am J Psychiatry 161 2004 157 159
147. T.L. Roth, F.D. Lubin, M. Sodhi, and J.E. Kleiman Epigenetic mechanisms in schizophrenia Biochim Biophys Acta 1790 2009 869 877
148. C. Rummel-Kluge, W. Kissling, and S. Leucht Antidepressants for the negative symptoms of schizophrenia Cochrane Database Syst Rev 3 2006 CD005581
149. M. Sarter, C.L. Nelson, and J.P. Bruno Cortical cholinergic transmission and cortical information processing in schizophrenia Schizophr Bull 31 2005 117 138
150. S.A. Schobel, N.H. Chaudhury, U.A. Khan, B. Paniagua, M.A. Styner, and I. Asllani Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver Neuron 78 2013 81 93
151. J.H. Schoemaker, W.T. Jansen, J. Schipper, and A. Szegedi The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: Results from the GIANT trial J Clin Psychopharmacol 34 2014 190 198
152. M.M. Sethom, S. Fares, N. Bouaziz, W. Melki, R. Jemaa, M. Feki, and et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia Prostaglandins Leukot Essent Fatty Acids 83 2010 131 136
153. S.S. Shafti, and M. Gilanipoor A comparative study between olanzapine and risperidone in the management of schizophrenia Schizophr Res Treat 2014 2014 307202
154. C. Shi, X. Yu, E.F.C. Cheung, D.H. Shum, and R.C. Chan Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis Psychiatry Res 215 2013 505 513
155. S. Shirazi-Southall, D.E. Rodriguez, and G.G. Nomikos Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat Neuropsychopharmacology 26 2002 583 594
156. J. Sin, and I. Norman Psychoeducational interventions for family members of people with schizophrenia: A mixed-method systematic review Br J Clin Psychol 74 2013 e1145 e1162
157. S.P. Singh, V. Singh, N. Kar, and K. Chan Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis Br J Psychiatry 19 2010 174 179
158. Y. Song, D. Liu, Y. Chen, and G. He Using focus groups to design a psychoeducation program for patients with schizophrenia and their family members Int J Clin Exp Med 7 2014 177 185
159. E. Spina, P. De Domenico, C. Ruello, N. Longobardo, C. Gitto, M. Ancione, and et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients Int Clin Psychopharmacol 9 1994 281 285
160. E. Stip, and V. Tourjman Aripripazole in schizophrenia and schizoaffective disorder: A review Clin Ther 32 2010 S3 S20
161. G.P. Strauss, W.R. Keller, R.W. Buchanan, J.M. Gold, B.A. Fischer, R.P. McMahon, and et al. Next-generation negative symptom assessment for clinical trials: Validation of the Brief Negative Symptom Scale Schizophr Res 142 2012 88 92
162. G.P. Strauss, J.A. Waltz, and J.M. Gold A review of reward processing and motivational impairment in schizophrenia Schizophr Bull 40 Suppl. 2 2014 S107 S116
163. R. Stryjer, Y. Dambinsky, I. Timinsky, T. Green, M. Kotler, A. Weizman, and et al. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: An open-label, prospective study Int Clin Psychopharmacol 28 2013 96 98
164. R. Tandon, and J.F. Greden Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia Arch Gen Psychiatry 46 1989 745 753
165. R. Tandon, and M.D. Jibson Extrapyramidal side effects of antipsychotic treatment: Scope of problem and impact on outcome Ann Clin Psychiatry 14 2002 123 129
166. W.K. Tang, and G.S. Unqvari Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: A prospective open trial Prog Neuropsychopharmacol Biol Psychiatry 27 2003 373 379
167. D.M. Taylor Reasons for discontinuing clozapine: Matched, case-control comparison with risperidone long-acting injection Br J Psychiatry 194 2009 165 167
168. D.M. Taylor, L. Smith, S.H. Gee, and J. Nielsen Augmentation of clozapine with a second antipsychotic - A meta-analysis Acta Psychiatr Scand 125 2012 15 24
169. A.V. Terry, and D.A. Gearhart Time dependent decreases in central α7 nicotine acetylcholine receptors associated with haloperidol and risperidone treatment in rats Eur J Pharmacol 571 2007 29 32
170. J. Tiihonen, P. Halonen, K. Wahlbeck, E. Repo-Tiihonen, S. Hyvärinen, M. Eronen, and et al. Topiramate add-on in treatment-resistant schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial J Clin Psychiatry 66 2005 1012 1015
171. M. Tomotake Quality of life and its predictors in people with schizophrenia J Med Invest 58 2011 167 174
172. M.T. Treadway, J.W. Buckholtz, A.N. Schwartzman, W.E. Lambert, and D.H. Zald Worth the 'EEfRT'? The effort expenditure for rewards task as an objective measure of motivation and anhedonia PLoS One 4 8 2009 e6598
173. C.H. Tsai, T.T. Chen, and W.L. Huang Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia Psychiatry Clin Neurosci 68 2014 582 583
174. G. Tsai, H.Y. Lane, P. Yang, M.Y. Chong, and N. Lange Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 55 2004 452 456
175. M.T. Tsuang, J.L. Bar, W.S. Stone, and S.V. Faraone Gene-environment interactions in mental disorders World Psychiatry 3 2004 73 83
176. D. Turkington, D. Kingdon, and P.J. Weiden Cognitive behavior therapy for schizophrenia Am J Psychiatry 163 2006 365 373
177. J. Usall, R. López-Carrilero, R. Iniesta, M. Roca, M. Caballero, R. Rodriguez-Jimenez, C. Oliveira, M. Bernardo, I. Corripio, S.D. Sindreu, J.C. González Piqueras, A.E. Felipe, B. Fernandez de Corres, A. Ibáñez, and R. Huerta Abordaje Síntomas Negativos Esquizofrenia Group. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia J Clin Psychiatry 75 6 2014 608 615
178. M. Valencia, A. Fresan, F. Juárez, R. Escamilla, and R. Saracco The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia J Psychiatr Res 47 2013 1886 1892
179. J. van Dongen, and D.I. Boomsma The evolutionary paradox and the missing heritability of schizophrenia Am J Med Genet (Part B) 162 2013 122 136
180. D.I. Velligan, and L.D. Alphs Negative Symptoms in Schizophrenia: An Update on Identification and Treatment Psychiatr Times 2014 http://www.psychiatrictimes.com/schizophrenia/negative-symptoms-schizophrenia-update-identification-and-treatment/page/0/1, accessed 06.28.2015
181. L.A. Volpicelli, and A.I. Levey Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus Prog Brain Res 145 2004 59 66
182. Y. Wang, Y. Fang, Y. Shen, and Q. Xu Analysis of association between the catechol-O-menthyltransferase (COMT) gene and negative symptoms in chronic schizophrenia Psychiatry Res 179 2010 147 150
183. R.D. Ward, E.H. Simpson, V.L. Richards, G. Deo, K. Taylor, J.I. Glendinning, and et al. Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia Neuropsychopharmacology 37 7 2012 1699 1707
184. A. Wassef, J. Baker, and L. Kochan GABA and Schizophrenia: A review of basic science and clinical studies J Clin Psychopharmacol 23 2003 601 640
185. D.R. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia Arch Gen Psychiatry 44 1987 660 669
186. M. Weiser, U. Heresco-Levy, M. Davidson, D.C. Javitt, N. Werbeloff, A.A. Gershon, and et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia J Clin Psychiatry 73 2012 728 734
187. J. Wess, R.M. Eglen, and D. Gautam Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development Nat Rev Drug Discov 6 2007 721 733
188. E. Williams, M. Ferrito, and J. Tapp Cognitive-behavioral therapy for schizophrenia in a forensic mental health setting J Forensic Practice 16 2014 68 77
189. 1) a susceptibility gene for schizophrenia? Schizophr Bull 31 2005 800 805
190. D.H. Wolf, T.D. Satterthwaite, J.J. Kantrowitz, N. Katchmar, L. Vandekar, M.A. Elliott, and et al. Amotivation in schizophrenia: Integrated assessment with behavioral, clinical, and imaging measures Schizophr Bull 40 6 2014 1328 1337
191. J. Xia, L.B. Merinder, and M.R. Belgamwar Psychoeducation for schizophrenia Cochrane Database Syst Rev 6 2011 CD002831
192. C. Xu, N. Aragam, X. Li, E.C. Villla, L. Wang, D. Briones, and et al. BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: Meta-analysis of two genome-wide association studies PLoS One 8 1 2013 e51674
193. D. Zullino, P. Delacrausaz, and P. Baumann The place of SSRIs in the treatment of schizophrenia Encéphale 28 5 Pt 1 2002 433 438